These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 2578185

  • 1. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
    Grafe MR, Forno LS, Eng LF.
    J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
    [Abstract] [Full Text] [Related]

  • 2. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP.
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [Abstract] [Full Text] [Related]

  • 3. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE, Landis DM, Zalneraitis EL.
    Brain Res; 1983 Dec 19; 289(1-2):11-26. PubMed ID: 6198034
    [Abstract] [Full Text] [Related]

  • 4. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease.
    Emson PC, Arregui A, Clement-Jones V, Sandberg BE, Rossor M.
    Brain Res; 1980 Oct 13; 199(1):147-60. PubMed ID: 6157454
    [Abstract] [Full Text] [Related]

  • 5. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis.
    Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, Vonsattel JP, DiFiglia M.
    Neuroscience; 1995 Jan 13; 64(2):397-404. PubMed ID: 7535402
    [Abstract] [Full Text] [Related]

  • 6. Opioid peptides in Huntington's disease: alterations in prodynorphin and proenkephalin system.
    Seizinger BR, Liebisch DC, Kish SJ, Arendt RM, Hornykiewicz O, Herz A.
    Brain Res; 1986 Jul 23; 378(2):405-8. PubMed ID: 2873872
    [Abstract] [Full Text] [Related]

  • 7. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E, Beal MF.
    Brain; 1993 Oct 23; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [Abstract] [Full Text] [Related]

  • 8. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M, Dragunow M, Faull RL.
    Neuroscience; 2000 Oct 23; 97(3):505-19. PubMed ID: 10828533
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.
    Zech M, Bogerts B.
    Acta Neuropathol; 1985 Oct 23; 68(1):32-8. PubMed ID: 2413707
    [Abstract] [Full Text] [Related]

  • 11. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL, Waldvogel HJ, Glass M, Faull RL.
    J Chem Neuroanat; 2009 Jul 23; 37(4):266-81. PubMed ID: 19481011
    [Abstract] [Full Text] [Related]

  • 12. Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases.
    Clevens RA, Beal MF.
    Brain Res; 1989 May 08; 486(2):387-90. PubMed ID: 2471578
    [Abstract] [Full Text] [Related]

  • 13. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration.
    Goto S, Hirano A, Matsumoto S.
    Neurology; 1990 Jul 08; 40(7):1051-6. PubMed ID: 2192300
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD.
    Brain; 1991 Aug 08; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [Abstract] [Full Text] [Related]

  • 17. Substance P and substance P receptor histochemistry in human neurodegenerative diseases.
    Kowall NW, Quigley BJ, Krause JE, Lu F, Kosofsky BE, Ferrante RJ.
    Regul Pept; 1993 Jul 02; 46(1-2):174-85. PubMed ID: 7692486
    [Abstract] [Full Text] [Related]

  • 18. Selective effects of partial and severe lesions of the serotonergic systems on Met-enkephalin and substance P neurons in rat basal ganglia.
    Compan V, Salin P, Daszuta A.
    Brain Res Mol Brain Res; 1997 Oct 15; 50(1-2):246-56. PubMed ID: 9406941
    [Abstract] [Full Text] [Related]

  • 19. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB, Whitehouse PJ, Folstein SE, Price DL, Vale WW.
    Brain Res; 1987 Dec 29; 437(2):355-9. PubMed ID: 2893655
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.